Drug Coated Balloon Improves Outcomes of Sub-optimal Supera Deployment in the Intermediate Term

Background: Sub-Optimal deployment of Self expanding interwoven stents (Supera) has been shown to increase the rate of Clinically Driven Target Lesion Revascularization (CD-TLR). Meanwhile, drug eluting balloons (DCB) have been shown to reduce CD-TLR in the femoral-popliteal segment in de- novo and restenotic lesions. However, the clinical effects of adjunctive DCB in nominal, compressed, and elongated Supera has not been widely studied . Objectives: The purpose of this study is to assess the outcomes of clinically driven re-intervention, major amputations, and mortality in relation to the adjunctive use of DCB in different deployment conditions (nominal, compressed, elongated) of the Supera stent. Methods: Patient chart data was collected at a single center hospital between March 2015 to May 2020. All patients were adults (≥18 years old) and were treated with at least one (≥1) Supera stent. Deployment status was extrapolated from anonymized angiograms. The primary endpoint of this study was CD-TLR. Secondary endpoints included amputation and mortality rates associated with each deployment condition. Results: A total of 670 limbs were treated and patients were followed for 36 months. Nominal stent deployment was observed in 337 limbs, followed by elongated condition (n=176), then by compressed conditions (n=159). CD-TLR was observed most frequently with elongated deployment. Adjunctive drug coated balloon use showed a protective effect regardless of deployment status; O.R=0.44 (CI: 0.30-0.66, p<.05). Conclusions: Adjunctive DCB with Supera deployment was found to provide a protective effect in reintervention regardless of deployment status.